Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Common Equity (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Common Equity for 9 consecutive years, with $32.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 166.3% to $32.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.6 million, a 166.3% increase, with the full-year FY2025 number at $32.6 million, up 166.3% from a year prior.
  • Common Equity was $32.6 million for Q4 2025 at Akebia Therapeutics, down from $41.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $213.9 million in Q1 2021 to a low of -$50.4 million in Q3 2024.
  • A 5-year average of $27.3 million and a median of $15.4 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: plummeted 684.78% in 2023, then skyrocketed 190.18% in 2025.
  • Akebia Therapeutics' Common Equity stood at $74.0 million in 2021, then plummeted by 92.93% to $5.2 million in 2022, then tumbled by 684.78% to -$30.6 million in 2023, then crashed by 60.82% to -$49.2 million in 2024, then surged by 166.3% to $32.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Common Equity are $32.6 million (Q4 2025), $41.6 million (Q3 2025), and $29.2 million (Q2 2025).